News and Announcements
Fintech startup Maqro releases hybrid robo-advice service
- Published March 21, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- Fintech start-up Maqro has released a hybrid robo-advice service in Australia, set to compete against traditional financial institutions.
- The robo-device allows investors to access high-quality financial advice from a real human and financial advisers can white-label the product and scale according to their business needs.
- Maqro is seeking additional funds of $2.2 million to further expand its offerings.
Fintech start-up Maqro, co-founded by Conrad Song, has released a hybrid robo-advice service in Australia, set to compete against traditional financial institutions. The robo device brings together the best of both worlds in terms of investing, for both the investor and advisers. It allows investors access to systematic algorithmic investment strategies online, all underpinned by real advice for a financial adviser.
The robo-device has closed the gap between those seeking individualised financial advice, and those limited by funds. It allows advisers to white-label the SaaS model and scale it according to their business needs. Robo-advice is leading the way as one of the most innovative AI applications today.
Maqro has raised $500, 000 to date and aims to raise an additional $2.2 million to expand its offerings.
About Maqro
A loss of faith in existing adviser services, combined with the growing popularity of self-serve digital solutions has heralded a boom in online investment advice.
Maqro is a startup on a mission to provide Australian investors with technology-driven solutions destined to give traditional financial institutions a run for their money.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
